|
|
|
| Preparation of Folic Acid/chitosan-Prdx6 shRNA Nanoparticles and Its Anti-carcinoma Effect on Gastric Cancer Cell Proliferation |
| XIN Lin, YANG Wei-feng, ZHANG Hou-ting, LI Yi-fan |
| The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China |
|
|
|
Abstract Aim:To investigate the effect of folate chitosan Prdx6 shRNA nanoparticles on the growth of gastric cancer cells. Methods:Prepared the targeting folate conjugated chitosan Prdx6 shRNA nanoparticles and observed nanoparticles morphology by atomic force microscope and particle size of nanoparticles by laser particle size analyzer;observed the folic acid chitosan Prdx6 shRNA nanoparticles transfection efficiency by nverted fluorescence microscope;detected gastric cancer cell prdx6 protein expression changes using Western blotting; detected gastric cancer cells survival rate by the methods of CCK-8. Results:Preparation of folate chitosan shRNA Prdx6 nanoparticles. Efficiency of folate-chitosan Prdx6 shRNA nanoparticles transfecting gastric cancer cell was significantly higher than that of non targeting nanoparticles by fluorescence microscope; Prdx6 protein expression of gastric cancer cells transfected by folate-chitosan Prdx6 shRNA nanoparticles was significantly lower than that of non targeting nanoparticles. Compared with the control group, folic acid chitosan shRNA Prdx6 nanoparticles could significantly inhibit the proliferation of gastric cancer cells (P<0.01). Conclusion:Folate chitosan shRNA Prdx6 nanoparticles can be efficiently transfected into gastric cancer cells. The growth of gastric cancer cells was significantly inhibited after transfection with folate chitosan shRNA Prdx6 nanoparticles.
|
|
Received: 08 August 2016
Published: 25 January 2017
|
|
|
|
|
| [1] Choi H, Chang J W, Jung Y K. Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ, 2011, 18(3):405-414.
[2] Wittrup A, Lieberman J.Knocking down disease:a progress report on siRNA therapeutics. Nat Rev Genet,2015,16(9):543-552.
[3] Tong L, Chuang C C, Wu S, et al. Reactive oxygen species in redox cancer therapy. Cancer Lett, 2015, 367(1):18-25.
[4] Kang S W, Lee S, Lee E K. ROS and energy metabolism in cancer cells:alliance for fast growth. Arch Pharm Res, 2015, 38(3):338-345.
[5] Glasauer A, Chandel N S. Targeting antioxidants for cancer therapy. Biochem Pharmacol, 2014, 92(1):90-101.
[6] Zhou S, Sorokina E M, Harper S, et al. Peroxiredoxin 6 homodimerization and heterodimerization with glutathione S-transferase pi are required for its peroxidase but not phospholipase A2 activity. Free Radic Biol Med,2016, 94:145-156.
[7] Ma S, Zhang X, Zheng L, et al. Peroxiredoxin 6 is a crucial factor in the initial step of mitochondrial clearance and Is upstream of the PINK1-parkin pathway. Antioxid Redox Signal, 2016, 24(9):486-501.
[8] Lee S B, Ho J N, Yoon S H, et al. Peroxiredoxin 6 promotes lung cancer cell invasion by inducing urokinase-type plasminogen activator via p38 kinase, phosphoinositide 3-kinase, and Akt. Mol Cells, 2009, 28(6):583-588.
[9] Ho J N, Lee S B, Lee S S, et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther, 2010, 9(4):825-832.
[10] Pak J H, Choi W H, Lee H M, et al. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest, 2011, 29(1):21-28.
[11] Gebremedhin S, Singh A, Koons S, et al. Gene delivery to carcinoma cells via novel non-viral vectors:nanoparticle tracking alysis and suicide gene therapy. Eur J Pharm Sci, 2014,60:72-79.
[12] Askar S, Abnous K, Taghavi S, et al. Cellular delivery of shRNA using aptamer-conjugated PLL-alkyl-PEI nanoparticles. Colloids Surf B Biointerfaces, 2015, 136:355-364. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
